Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to $6.3 million.

  • Vanda Pharmaceuticals' Gains from Investment Securities rose 79928.26% to $6.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 million, marking a year-over-year increase of 31046.51%. This contributed to the annual value of $2.0 million for FY2025, which is 31046.51% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Gains from Investment Securities of $6.3 million as of Q4 2025, which was up 79928.26% from -$1.4 million recorded in Q3 2025.
  • Vanda Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $6.3 million during Q4 2025, with a 5-year trough of -$1.9 million in Q1 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median Gains from Investment Securities value was -$554000.0 (recorded in 2021), while the average stood at -$261700.0.
  • Within the past 5 years, the most significant YoY rise in Vanda Pharmaceuticals' Gains from Investment Securities was 79928.26% (2025), while the steepest drop was 18907.96% (2025).
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Gains from Investment Securities stood at -$506000.0 in 2021, then plummeted by 66.8% to -$844000.0 in 2022, then skyrocketed by 180.21% to $677000.0 in 2023, then increased by 2.95% to $697000.0 in 2024, then soared by 799.28% to $6.3 million in 2025.
  • Its Gains from Investment Securities stands at $6.3 million for Q4 2025, versus -$1.4 million for Q3 2025 and -$1.0 million for Q2 2025.